Clinical Trial Update: Efficacy and Safety of IL-11 in DDAVP Unresponsive [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of interleukin-11 in DDAVP-unresponsive bleeding in Hemophilia A and Von Willebrand disease; the study has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia
• Von Willebrand Disease

Drugs mentioned

• Interleukin-11 (oprelvekin) (oprelvekin)

Snippet

Sponsor: University of Pittsburgh | Conditions: Hemophilia A, Von Willebrand Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-03-02